To the Editor: A recent article by Lintzeris and colleagues,1 ostensibly about naltrexone implants, actually has little to do with implant treatment. Only one of the 12 reported cases involved problems linked specifically to naltrexone (antagonist) treatment being administered in implanted rather than oral form. This case involved infection at the implant site — undesirable, certainly, but about as noteworthy as the occasional infections that occur after abdominal surgery or breast implantation, despite antibiotic prophylaxis and careful technique. The remaining 11 admissions reflected not implant use but either the procedure of rapid antagonist induction (RAI) or the desired pharmacological effects for which naltrexone was prescribed in the first place (and one admission for unrelated pneumonia).
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Lintzeris N, Lee S, Scopelliti L, et al. Unplanned admissions to two Sydney public hospitals after naltrexone implants. Med J Aust 2008; 188: 441-444. <MJA full text>
- 2. Strang J, McCambridge J, Best D, et al. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ 2003; 326: 959-960.
- 3. Laheij RJF, Krabbe PFM, De Jong CAJ. Rapid heroin detoxification under general anesthesia [letter]. JAMA 2000; 283: 1143.
- 4. Currie J, Collins L, Mudaliar Y, et al. Rapid induction onto naltrexone: a randomised clinical trial of anesthesia-assisted versus sedation-assisted techniques, and a comparison with conventional opiate detoxification. Report to the Government of New South Wales. Sydney: Western Sydney Area Health Service Drug and Alcohol Service, 2000.
- 5. Kunøe N, Lobmaier PP, Waal H. A randomized prospective trial of naltrexone implants for opioid dependence [abstract]. The 9th Stapleford International Addiction Conference; 2008 May 23–26; Athens, Greece. http://www.stapleford-athens.net (accessed Aug 2008).
- 6. Krupitsky E, Zvartau E, Egorova V, et al. A double-blind, placebo controlled randomized clinical trial of long acting implantable formulation of naltrexone for heroin dependence: results of interim analysis [abstract]. The 9th Stapleford International Addiction Conference; 2008 May 23–26; Athens, Greece. http://www.stapleford-athens.net (accessed Aug 2008).
- 7. Hulse GK, Low V, Stalenberg V, et al. Tissue compatability, biodegradability, blood naltrexone levels, and heroin overdose following treatment of heroin dependent persons with sustained release naltrexone-poly(dl-lactide) implants. (Study 5: Randomised double-blind placebo controlled clinical trial compared to oral naltrexone.) [abstract]. The 9th Stapleford International Addiction Conference; 2008 May 23–26; Athens, Greece. http://www.stapleford-athens.net (accessed Aug 2008).
- 8. Lobmaier P, Kunøe N, Waal H. Naltrexone implants compared to methadone maintenance treatment for opioid dependence among pre-release inmates [abstract]. The 9th Stapleford International Addiction Conference; 2008 May 23–26; Athens, Greece. http://www.stapleford-athens.net (accessed Aug 2008).
- 9. Hulse GK, Tait RJ, Comer SD, et al. Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend 2005; 79: 351-357.
- 10. Brewer C. Response to Degenhardt et al: “depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy”. Drug Alcohol Rev 2008; 27: 447-448.
I receive some income from a private clinic that provides, inter alia, both agonist and antagonist treatment for opiate addicts.